Khulood A. Qasem

Dr. Khulood A. Qasem

Medicine and Surgery, Sulaiman Al Rajhi Colleges, Al Bukayrīyah, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Helal HettaHelal Hetta
Helal Hetta
MAMostafa Ali
Mostafa Ali
SASaleh F Alqifari
Saleh F Alqifari
HSHoda Abdelaziz Salem
Hoda Abdelaziz Salem
KQKhulood A. Qasem
Khulood A. Qasem
Reem SayadReem Sayad
Reem Sayad
Background/Objectives: Non-small-cell lung cancer (NSCLC) frequently metastasizes to the brain, significantly impacting patient prognosis and quality of life. Anlotinib, a novel tyrosine kinase inhibitor, has shown promise in treating NSCLC with brain metastasis. So, we aimed to evaluate the clinical efficacy of anlotinib and various types of radiotherapy combinations used to treat NSCLC patients with brain metastasis regarding overall survival and the treatment of internal and external lesions. Methods: A comprehensive literature search was conducted in the databases PubMed, Scopus, WoS, MedLine, and Cochrane Library up to April 2024. Studies assessing the efficacy of anlotinib combined with whole-brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), or other radiotherapy modalities in NSCLC patients with brain metastasis were included. The primary outcomes were (a) the efficacy of anlotinib and radiotherapy on the intracranial lesions and OS and (b) the effectiveness of combined anlotinib and radiotherapy versus radiotherapy alone in NSCLC patients with brain metastasis. The secondary outcome was the efficacy of anlotinib and radiotherapy on extracranial progression. We used a combination of keywords and MeSH terms including ‘non-small cell lung cancer’ OR ‘NSCLC’, ‘brain metastases’, ‘anlotinib’, ‘radiotherapy’, ‘radiation therapy’, and ‘combined treatment’, among others. Boolean operators (AND, OR) were applied as appropriate to optimize the search strategy across databases. Results: Nine studies met the inclusion criteria, comprising 210 patients in the combination group and 228 patients in the radiotherapy alone group. The combination of anlotinib with radiotherapy showed a significant improvement in iPFS compared to radiotherapy alone, with a pooled risk ratio (RR) for iORR of 1.18 (95% CI: 1.00–1.39) and a pooled SMD for OS of 0.03 (95% CI: −0.29, 0.36). Radiotherapy combined with anlotinib also demonstrated enhanced intracranial and extracranial control rates. Conclusions: Anlotinib combined with radiotherapy, especially WBRT, offers a promising treatment strategy for NSCLC patients with brain metastasis, improving intracranial control. Further large-scale randomized controlled trials are needed to confirm these findings and optimize treatment protocols.

1 January 2026 in Patient Preference and Adherence
Verified
Journal Article
Open access
SASaleh F Alqifari
Saleh F Alqifari
PAPalanisamy Amirthalingam
Palanisamy Amirthalingam
Kousalya PrabaharKousalya Prabahar
Kousalya Prabahar
KQKhulood A. Qasem
Khulood A. Qasem
FAFawaz Alanazi
Fawaz Alanazi
AAAhmed Aljabri
Ahmed Aljabri
Patient satisfaction is crucial in managing chronic diseases like diabetes mellitus (DM). This study aims to identify the key factors associated with patient satisfaction with DM treatment in the Kingdom of Saudi Arabia. This cross-sectional study collected data from 709 participants country-wide via an online survey. Participants included patients receiving care from public and private healthcare facilities offering primary or specialized diabetes care. Patient satisfaction was assessed using the Diabetes Treatment Satisfaction Questionnaire (DTSQs), with chi-square tests for HbA1c control and Mann–Whitney U-tests for comparisons of means between groups. Governmental healthcare patients had higher satisfaction (Mean = 27.32, SD = 7.62) than private (Mean = 25.5, SD = 8.51) (p = 0.007). Patient treatment satisfaction was also greater in diabetes centers (Mean = 28.93, SD = 6.34), than in primary care (Mean = 25.45, SD = 8.51), (p= <0.001). Although overall treatment satisfaction scores did not differ significantly between controlled and uncontrolled diabetes (p= 0.784), patients with controlled diabetes experienced significantly fewer hyperglycemic and hypoglycemic episodes, (p= <0.001), and higher satisfaction with treatment flexibility (p= 0.006), diabetes understanding (p= 0.013) and willingness to recommend their treatment to others (p= <0.001). Mode of healthcare delivery (public or private hospitals) and choice between primary care or diabetes centers was significantly associated with treatment satisfaction with greater satisfaction in governmental healthcare and specialized diabetes centers. Glycemic control, measured by HbA1c, showed no significant association with overall treatment satisfaction but was associated with specific item scores (including satisfaction with understanding and treatment flexibility). This study is among the first in Saudi Arabia to compare DM treatment satisfaction across different healthcare settings using the DTSQs. Recognizing these associations can provide healthcare professionals with valuable insights for more successful treatment of diabetes patients and ultimately improve patient outcomes.